Washington Examiner
Sign in Subscribe
News
Politics
White House
Senate
House
Campaigns
Business
World
Investigations
Justice
Supreme Court
Crime
Entertainment
Washington Secrets
Policy
Defense
National Security
Energy and Environment
Education
Immigration
Finance and Economy
Healthcare
Foreign Policy
Tech
Infrastructure
Space
2026 Election
America at 250
IN FOCUS
Commentary
Columnists
Editorials
Think Tanks
Beltway Confidential
Op-Eds
Restoring America
Patriotism and Unity
Faith, Freedom, and Self-Reliance
Courage, Strength, and Optimism
Equality, Not Elitism
Community and Family
Fairness and Justice
Mission
Watch
Magazine
Magazine
Quarterly Briefing
Archives
Games
Sponsored
Protecting Air Ambulance Services
Powering Progress
ASAE – Association Leadership
National Parks
Examining Tax Reform
Fix TSCA
Inside the Corn Belt
Examining Transportation
Newsletters
Sign In Sign InHome
News
Politics
Policy2026 Election
Opinion
EditorialsOp-Eds
In FocusRestoring AmericaMagazineWatch
Sponsored
Protecting Air Ambulance ServicesPowering ProgressASAE – Association LeadershipNational ParksExamining Tax ReformFix TSCAInside the Corn BeltExamining Transportation
TWS Archive
Advertisement
Home › Tags › Posts tagged Pharmaceutical Industry

Tag: Pharmaceutical Industry

A new reports shows that Wisconsin Sen. Ron Johnson, running for reelection, is the most productive senator when it comes to getting legislation passed. (AP Photo/Scott Bauer, File) Healthcare

Dispute over helping the terminally ill

Paige Winfield Cunningham · June 27, 2016 4:01 am
AIDS advocates participate in a rolling protest caravan in Rancho Palos Verdes, Calif., on June 8, targeting Gilead Sciences over its drug pricing and policies during the drug giant's presentation at Goldman Sachs' Annual Healthcare Conference at the exclusive Terranea Resort. The protest followed a Los Angeles Times article that revealed Gilead's patent manipulation in order to maximize profits on its drugs containing tenofovir, a key HIV/AIDS drug. (AIDS Healthcare Foundation via AP) Healthcare

Drug makers fight Calif. price caps

Robert King · June 13, 2016 4:01 am
Sens. Susan Collins, R-Maine, and Claire McCaskill, D-Mo., wrote to five manufacturers of naloxone on Friday to ask what the drug companies are doing to preserve access to the generic product. (AP Photo/Mel Evans, File) Healthcare

Senators want cheap prices for overdose antidote

Robert King · June 6, 2016 9:02 pm
Shkreli was hit on Friday with a new indictment that included a new conspiracy charge. The charges are related to allegations that Shkreli and his former attorney Evan Greebel took stock from one company to prop up another. (Pete Marovich/Bloomberg, File) Healthcare

‘Pharma bro’ pleads not guilty to new charges

Robert King · June 6, 2016 7:32 pm
Benjamin Brafman, right, attorney for pharmaceutical chief Martin Shkreli, foreground, speaks on Capitol Hill on Feb. 4 during a House Committee on Oversight and Reform Committee hearing on rising drug prices. Shkreli refused to testify before U.S. lawmakers who excoriated him over severe hikes for a drug sold by a company that he acquired. (AP Photo/Susan Walsh) Healthcare

Lawmakers feel the pain over drug prices

Paige Winfield Cunningham · June 6, 2016 4:01 am
Former drug company CEO Martin Shrkeli has been hit with a new conspiracy charge. (AP Photo/Craig Ruttle) Crime

‘Pharma Bro’ slapped with another charge

Daniel Chaitin · June 4, 2016 5:03 pm
The agency on Thursday finalized a rule that streamlines the process of applying for compassionate use, which enables a patient to get non-approved treatments when there isn’t any other option. (iStock photo) Healthcare

FDA speeds up process of applying for last resort drugs

Robert King · June 2, 2016 2:57 pm
Rep. Mike Bishop, R-Mich., said Wednesday the administration hasn't answered his questions about why it didn't grant emergency funds to victims in a 2012 outbreak of meningitis. (AP Photo/Susan Walsh, File) Healthcare

Lawmaker wants funds for victims of tainted drug scandal

Robert King · June 1, 2016 2:50 pm
Republicans want the Obama administration to allow drug firms to advertise unapproved drug uses to doctors. (AP Photo/Sue Ogrocki, File) Healthcare

House lawmakers push HHS on drug advertising

Robert King · May 26, 2016 10:58 pm
The Food and Drug Administration approved Probuphine, which is an implant intended to provide a low-level dose of the opioid addiction treatment buprenorphine. (Screenshot) Healthcare

FDA approves new way to fight opioid addiction

Robert King · May 26, 2016 9:29 pm
The FDA is putting off a decision on whether to approve a controversial drug that patient advocates and some senators say is the only hope for children with Duchenne Muscular Dystrophy. (iStock Photo) Healthcare

FDA delays decision on controversial drug

Robert King · May 25, 2016 4:16 pm
Two Republican senators, including Wisconsin Sen. Ron Johnson, are disappointed that a panel of experts did not recommend a new drug called Sarepta for Duchenne muscular dystrophy, a fatal disease that mainly affects young boys. (AP Photo/Susan Walsh, File) Healthcare

Senators push FDA to approve drug for rare disease

Robert King · May 23, 2016 10:15 pm
Advertisement
  • ‹Previous page
  • 1
  • …
  • 112
  • 113
  • 114
  • 115
  • 116
  • …
  • 142
  • ›Next page
Page 114 of 142
Advertisement
Washington Examiner Manage Preferences

News

  • Politics
    • White House
    • Senate
    • House
    • Campaigns
  • Business
  • World
  • Investigations
  • Justice
  • Supreme Court
  • Crime
  • Washington Secrets
  • Entertainment
  • Sports

Policy

  • Defense
  • National Security
  • Energy
  • Immigration
  • Finance and Economy
  • Healthcare
  • Foreign Policy
  • Tech
  • Infrastructure
  • Space

Commentary

  • Columnists
  • Editorials
  • Think Tanks
  • Beltway Confidential
  • Op-Eds

Restoring America

  • Patriotism & Unity
  • Faith, Freedom & Self-Reliance
  • Courage, Strength & Optimism
  • Equality, Not Elitism
  • Community & Family
  • Fairness & Justice
  • Mission

Watch

  • Shows
NEWSLETTERS MAGAZINE ARCHIVE
  • Policies and Standards
  • Terms Of Service
  • Subscription Terms of Use
  • Privacy Policy
  • Your Privacy Choices
  • Transparency In Coverage
  • Advertise
  • Subscribe
  • Contact
  • Careers
  • Staff
  • About Examiner
  • Facebook
  • Twitter
© Copyright 2026. Washington Examiner. All Rights Reserved.
Advertisement